Please login to the form below
Glybera
This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.
J&J bolsters gene therapy unit with $100m MeiraGTx deal
In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.
Latest news
-
AZ makes gene therapy move with 4DMT alliance
While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
-
UniQure’s starts pivotal haemophilia B gene therapy trial
UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
-
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
-
NICE backs GSK’s €594k gene therapy for rare disease
Strimvelis was approved by the EMA in 2016 - the second gene therapy to get a green light anywhere in the world after UniQure’s $1m Glybera (alipogene tiparvovec) product for lipoprotein
-
Spark’s Luxturna becomes US’s first approved gene therapy
UniQure charged $1m for its Glybera (alipogene tiparvovec) product for lipoprotein lipase deficiency (LPLD) - the first gene therapy approved in Europe - but that product was withdrawn from the market this year
More from news
Approximately 3 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
-
Health on instalment
Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
-
Rare diseases: meeting the challenge
Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
-
Pharma deals in April 2015
Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per
-
Anticipating the future in healthcare
As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Digital Account Director
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Project Manager/ Account Manager
-
Salary TBC
Subscribe to our email news alerts
- Lighthouse Medical Commuications US appoints Lisa Druce as its new Managing Partner
- GW Pharma's cannabis-based medicine to be tested in dementia
- International Childhood Cancer Day 2019
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- Merck puts prostate cancer firmly in Keytruda’s sights
- Biosimilar Herceptin helps Roche gain new Perjeta recommendation
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
- Mixing up Focus Groups
- A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Quick links
Infographics
